LivaNova PLC
NASDAQ:LIVNMedical - Devices
+$0.76 today
- Market cap
- $5.21B
- Beta
- 0.88
- P/E (TTM)
- 40.5
- EPS (TTM)
- $1.96
Volume 1.32M
Average 0.79M
LIVN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
LivaNova PLCNASDAQ: LIVN
Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026
Accounts receivables turns negative
Q3 FY2026 accounts receivables was -$5.3M, compared with $7.84M a year earlier. Trailing-twelve-month accounts receivables was -$27.33M. Over 3 fiscal years it compounded at +30.6% a year.
Context
- Accounts receivables amounted to 0.8% of revenue in FY2025, down 0.1 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$5.3M or moves back toward the trailing-twelve-month quarterly average of -$6.83M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (10.7M) USD
- Year-over-year change
- -196.4%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.7M) | -196.4% |
| FY2024 | 2024-12-31 | 11.1M | +138.5% |
| FY2023 | 2023-12-31 | (28.86M) | -501.3% |
| FY2022 | 2022-12-31 | (4.8M) | +69.5% |
| FY2021 | 2021-12-31 | (15.75M) | — |
Accounts Receivables vs competitors
How LIVN compares with its peers on the latest reported figures
- LIVN's LTM Sep 2026 accounts receivables of $27.33M is the 6th largest of the 10 companies compared; the peer median is $18.14M.
- Its year-over-year change of +124.1% is the 4th highest of 10, against a peer median of +103.9%.
- Accounts receivables amounts to 1.8% of revenue for LIVN, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $293M | +144.2% | +6.9% | 1.4% | |
| LTM Jul 2026 | $264M | +3.5% | -29.7% | 0.7% | |
| LTM Jun 2026 | $156.35M | +103.9% | -3.1% | 2.8% | |
| LTM Jun 2026 | $82.5M | -197.5% | -35.1% | 1.3% | |
| LTM Jun 2026 | $34.3M | +159.0% | -1.0% | 3.8% | |
| LTM Sep 2026 | $27.33M | +124.1% | +30.6% | 1.8% | |
| LTM Jun 2026 | $18.14M | -813.4% | -15.2% | 1.3% | |
| LTM Mar 2026 | $7.18M | +294.6% | — | 4.7% | |
| LTM Mar 2026 | $647K | +117.0% | +67.3% | 0.7% | |
| LTM Mar 2026 | $92K | -82.2% | -22.0% | 0.2% | |
MOBIMobia Medical, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LIVN) | $18.14M | +103.9% | -9.2% | 1.3% | |
Competitors are the stored peer set for LIVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (135.82M) | (86.2M) | 17.55M | 63.23M | (242.5M) |
| Depreciation & Amortization | 67.99M | 57.8M | 60.86M | 51.14M | 42M |
| Deferred Income Tax | 2.85M | 1.4M | (114.43M) | 6.8M | 500K |
| Stock-Based Compensation | 40.56M | 44.81M | 36.35M | 33.93M | 36.3M |
| Change in Working Capital | 29.22M | (31.7M) | (34.62M) | 1.31M | 369.97M |
| Accounts Receivables | (15.75M) | (4.8M) | (28.86M) | 11.1M | (10.7M) |
| Inventory | 4.48M | (25.7M) | (28.48M) | (6.8M) | (5.3M) |
| Accounts Payables | 12.99M | (3.5M) | 19.19M | (14.5M) | (13.4M) |
| Other Working Capital | 27.49M | 2.3M | 3.53M | 11.51M | 399.41M |
| Other Non-Cash Items | 97.74M | 83.8M | 109.21M | 26.63M | 48.03M |
| Operating Cash Flow | 102.54M | 69.9M | 74.91M | 183.04M | 254.3M |
| Capital Expenditures | (25.48M) | (26.5M) | (34.98M) | (47.11M) | (81.1M) |
| Acquisitions (Net) | 41.25M | (8.9M) | 0 | 0 | 0 |
| Purchases of Investments | (3.65M) | (3M) | (6.5M) | (1.14M) | (5.7M) |
| Sales of Investments | 23.06M | 88K | 0 | 0 | 6.5M |
| Other Investing Activities | 1.73M | (88K) | 1.15M | 89K | 7.4M |
| Investing Cash Flow | 36.9M | (38.4M) | (40.33M) | (48.16M) | (72.9M) |
| Debt Repayment | (487.85M) | 284.01M | 26.4M | 87.97M | (280.93M) |
| Common Stock Issued | 309.62M | 0 | 0 | 0 | 35K |
| Common Stock Repurchased | (12.94M) | (8.7M) | (7.5M) | (8.44M) | (4.43M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.69M | 4.8M | 2.59M | (60.98M) | (378K) |
| Financing Cash Flow | (181.48M) | 280.1M | 21.48M | 18.55M | (285.7M) |
| Effect of Forex Changes | (2.81M) | (4M) | 6.19M | (7.75M) | 16.2M |
| Net Change in Cash | (44.84M) | 307.6M | 62.25M | 145.68M | (88M) |
| Free Cash Flow | 77.07M | 43.4M | 39.93M | 135.93M | 173.2M |
LivaNova PLC
NASDAQ:LIVN
Intrinsic Alpha fair value
Locked
Current Price
$94.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.